AssetMark Inc
SUPN icon

AssetMark Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

AssetMark Inc’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.1M Sell
48,839
-874
-2% -$39.8K ﹤0.01% 938
2026
Q2 		$2.31M Buy
49,713
+5,741
+13% +$276K ﹤0.01% 917
2026
Q1 		$2.27M Buy
43,972
+2,578
+6% +$131K ﹤0.01% 858
2025
Q4 		$2.06M Buy
41,394
+1,670
+4% +$81.2K ﹤0.01% 846
2025
Q3 		$1.9M Buy
39,724
+3,020
+8% +$122K ﹤0.01% 823
2025
Q2 		$1.16M Sell
36,704
-1,259
-3% -$40.3K ﹤0.01% 894
2025
Q1 		$1.24M Buy
37,963
+4,748
+14% +$168K ﹤0.01% 827
2024
Q4 		$1.2M Sell
33,215
-227
-0.7% -$7.99K ﹤0.01% 811
2024
Q3 		$1.04M Buy
33,442
+908
+3% +$28.3K ﹤0.01% 773
2024
Q2 		$870K Buy
32,534
+1,432
+5% +$41.5K ﹤0.01% 798
2024
Q1 		$1.06M Buy
31,102
+1,403
+5% +$41.8K ﹤0.01% 718
2023
Q4 		$859K Buy
29,699
+1,121
+4% +$29.7K ﹤0.01% 710
2023
Q3 		$788K Buy
28,578
+629
+2% +$19.1K ﹤0.01% 660
2023
Q2 		$840K Buy
27,949
+1,956
+8% +$68.4K ﹤0.01% 642
2023
Q1 		$942K Buy
25,993
+1,423
+6% +$54.7K ﹤0.01% 611
2022
Q4 		$876K Buy
24,570
+558
+2% +$19.4K ﹤0.01% 604
2022
Q3 		$813K Buy
24,012
+22,107
+1,160% +$719K ﹤0.01% 560
2022
Q2 		$55K Buy
1,905
+283
+17% +$8.11K ﹤0.01% 897
2022
Q1 		$52K Sell
1,622
-15
-0.9% -$460 ﹤0.01% 912
2021
Q4 		$48K Buy
1,637
+53
+3% +$1.61K ﹤0.01% 920
2021
Q3 		$42K Buy
1,584
+15
+1% +$403 ﹤0.01% 816
2021
Q2 		$48K Sell
1,569
-3
-0.2% -$92 ﹤0.01% 759
2021
Q1 		$41K Buy
1,572
+81
+5% +$2.26K ﹤0.01% 757
2020
Q4 		$38K Buy
1,491
+161
+12% +$3.46K ﹤0.01% 756
2020
Q3 		$28K Buy
1,330
+420
+46% +$9.5K ﹤0.01% 773
2020
Q2 		$22K Buy
910
+846
+1,322% +$18.7K ﹤0.01% 784
2020
Q1 		$1K Sell
64
-22
-26% -$462 ﹤0.01% 1298
2019
Q4 		$2K Buy
86
+8
+10% +$194 ﹤0.01% 1259
2019
Q3 		$2K Buy
+78
New +$2.31K ﹤0.01% 1185
2018
Q1 		– Sell
-17
Closed -$1K – 1949
2017
Q4 		$1K Buy
+17
New +$672 ﹤0.01% 1712

Other funds holding SUPN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Campbell Newman Asset Management
Campbell Newman Asset Management Milwaukee, Wisconsin $1.33B AUM 26.63% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

AssetMark Inc's SUPN Position: Q3 2026 in Review

AssetMark Inc reduced its Supernus Pharmaceuticals (SUPN) stake by 1.8% in Q3 2026, selling an estimated $39.8K and leaving 48,839 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #938.

AssetMark Inc first reported a position in SUPN in Q4 2017 and has held it in 30 quarters since. The position peaked at $2.31M in Q2 2026. 101 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

  • AssetMark Inc held 48,839 shares of Supernus Pharmaceuticals worth $2.1M as of Q3 2026.
  • AssetMark Inc sold 874 Supernus Pharmaceuticals shares in Q3 2026, an estimated $39.8K.
  • Supernus Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #938 holding.
  • AssetMark Inc first reported a position in Supernus Pharmaceuticals in Q4 2017 and has held it in 30 quarters since.
  • AssetMark Inc's Supernus Pharmaceuticals position peaked at $2.31M in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.